Analyst says acquisition strengthens Coloplast's core competencies

The acquisition of the Swedish company Atos Medical could lay the foundation for further top line growth and increased revenue for Coloplast, a Sydbank analyst assesses.

BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Published: 08.11.21 at 10:35

Coloplast's acquisition of Atos Medical could prove to be a solid growth driver within the Danish medtech company's chronic care business, says Senior Analyst at Sydbank Søren Løntoft Hansen.

Atos Medical is right up Coloplast's alley when it comes to its core competencies, and could therefore pave the way for further growth in terms of top line and revenue, he assesses.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.